Additionally, the 36-month beta value for CHRO is 3.51. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CHRO is 0.88M and currently, short sellers hold a 8.74% ratio of that float. The average trading volume of CHRO on June 27, 2025 was 698.16K shares.
CHRO) stock’s latest price update
Channel Therapeutics Corporation (AMEX: CHRO)’s stock price has dropped by -1.28 in relation to previous closing price of 1.17. Nevertheless, the company has seen a gain of 0.43% in its stock price over the last five trading days. globenewswire.com reported 2025-06-27 that FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) — Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”). The Reverse Stock Split is intended to increase the market price per share of the Company’s Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the “NYSE American”) in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned subsidiary of the Company, with and into LNHC, Inc. and the related approximately $50 million in capital to be raised from a group of strategic investors led by Murchinson (together, the “Proposed Transactions”).
CHRO’s Market Performance
Channel Therapeutics Corporation (CHRO) has experienced a 0.43% rise in stock performance for the past week, with a 19.69% rise in the past month, and a -21.96% drop in the past quarter. The volatility ratio for the week is 6.19%, and the volatility levels for the past 30 days are at 9.21% for CHRO. The simple moving average for the past 20 days is -1.13% for CHRO’s stock, with a 0.13% simple moving average for the past 200 days.
CHRO Trading at -1.27% from the 50-Day Moving Average
After a stumble in the market that brought CHRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.61% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CHRO starting from Malamut Richard, who purchase 10,400 shares at the price of $0.94 back on Sep 12 ’24. After this action, Malamut Richard now owns 91,565 shares of Channel Therapeutics Corporation, valued at $9,825 using the latest closing price.
Francis Knuettel II, the CEO, Pres., CFO, Treas & Secty of Channel Therapeutics Corporation, purchase 3,500 shares at $0.97 during a trade that took place back on Sep 13 ’24, which means that Francis Knuettel II is holding 547,710 shares at $3,395 based on the most recent closing price.
Stock Fundamentals for CHRO
The total capital return value is set at 1.78.
Currently, EBITDA for the company is -7.57 million with net debt to EBITDA at 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.39.
Conclusion
In conclusion, Channel Therapeutics Corporation (CHRO) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
